Active Biotech wins Japan patent for laquinimod eye-drop formulation through 2042

Bitget2026/09/30 09:02

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Active Biotech secured a Japan patent for an ophthalmic laquinimod formulation, strengthening its intellectual property position in a key pharmaceutical market.
The grant provides potential market exclusivity in Japan until 2042 under patent number 7,918,190.
The eye-drop formulation targets delivery to the back of the eye for severe inflammatory diseases, including non-infectious uveitis.
Management aims to move laquinimod into Phase II uveitis trials with a commercial partner; partnering discussions are ongoing.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Active Biotech AB published the original content used to generate this news brief on September 30, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Active Biotech wins Japan patent for laquinimod eye-drop formulation through 2042

You may also like

Crypto prices